We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
National Vision Gains 116.9% in a Year: What's Driving the Rally?
Read MoreHide Full Article
Key Takeaways
National Vision shares surged 116.9% in a year, far outperforming industry decline and S&P 500 gains.
EYE's growth is driven by premium products, new stores, and targeting underserved customer segments.
National Vision projects 2026 revenues of $2.03B-$2.09B and EPS of $0.85-$1.09 amid cost pressures.
National Vision (EYE - Free Report) has witnessed strong momentum over the past year. Shares of the company have risen 116.9%, outperforming the industry’s 16.5% decline. The S&P 500 composite has increased 29.7% during the same time frame.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.
National Vision is a major optical retailer in the United States. As of 2025, the company operated through a diverse portfolio of 1,250 retail stores across four brands, along with associated omnichannel consumer websites. National Vision operates through one reportable segment, Owned & Host, which includes two owned brands — America’s Best Contacts and Eyeglasses (America’s Best) and Eyeglass World.
Factors Favoring EYE’s Share Price Growth
National Vision’s share price is trending upward, prompted by its ongoing strategic transformation. The strategy focuses on four growth areas. In 2025, National Vision targeted underserved segments like managed care users and progressive lens wearers, boosting traffic. It also expanded premium and branded products, increasing sales and attracting higher-income customers, with strong performance from smart glasses and advanced lenses.
EYE is using data-driven segmentation to improve customer experience, personalize marketing and enhance sales practices, while leveraging its optometry network and technology to support steady expansion into new markets and formats.
In 2026, the company plans to open approximately 30 to 35 new stores, primarily comprising America’s Best locations, before returning to its more typical store opening cadence as strategic initiatives begin to take hold. New store openings are expected to remain a key driver of growth in net revenues and operating profit.
Investors are currently focused on the company’s strong market share gain in the Owned & Host segment. The segment continues to gain from positive comparable store sales growth and new store openings. Of the two Owned brands, America’s Best remains the primary revenue driver.
In the fourth quarter of 2025, adjusted comparable store sales growth was 4.8%. Remote exam technology remains central to National Vision’s ability to deliver care at scale. The company is making progress with its remote hybrid model, where in-store doctors also perform exams in other stores remotely. The program continues to expand, with more doctors being trained and participating.
National Vision’s 2026 outlook looks encouraging. Net revenues are projected to be in the range of $2.033-$2.091 billion. Adjusted EPS is estimated to be between 85 cents and $1.09.
Image Source: Zacks Investment Research
Factors That May Offset EYE’s Gains
EYE’s business remains vulnerable to growing geopolitical complexities, supply-chain disruptions, shortages of healthcare staff and volatility in capital markets. Additionally, the ongoing changes in U.S. trade policy and retaliatory tariffs look discouraging. All these factors continue to weigh on its profitability. In the fourth quarter of 2025, SG&A expenditures rose 12.1% year over year.
From a solvency viewpoint, National Vision has a significant amount of indebtedness. It exited the fourth quarter of 2025 with cash and cash equivalents of $39 million and short-term debt of $17 million. Long-term debt was $229 million, much higher than cash levels. This leverage could have several consequences, including greater exposure to adverse economic, industry or competitive developments.
A Look at EYE’s Estimates
The Zacks Consensus Estimate for 2026 EPS has remained unchanged at 93 cents in the past 30 days.
The company has an estimated long-term EPS growth rate of 20.1% compared with the industry’s 10.4%.
Globus Medical has an earnings yield of 4.9%, well ahead of the industry’s -0.7% yield. Its earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 18.8%. The company’s shares have rallied 22.3% against the industry’s 3.8% decline over the past year.
ALC, carrying a Zacks Rank #2 (Buy) at present, has an earnings yield of 4.4% against the industry’s -1.1% yield. Shares of the company have lost 13.9% against the industry’s 2.3% growth. ALC’s earnings topped estimates in two of the trailing four quarters and missed in the other two, the average surprise being 1.1%.
Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 6.1% compared with the industry’s 2.6% yield. Shares of the company have climbed 130.6% against the industry’s 17.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 20.2%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
National Vision Gains 116.9% in a Year: What's Driving the Rally?
Key Takeaways
National Vision (EYE - Free Report) has witnessed strong momentum over the past year. Shares of the company have risen 116.9%, outperforming the industry’s 16.5% decline. The S&P 500 composite has increased 29.7% during the same time frame.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.
National Vision is a major optical retailer in the United States. As of 2025, the company operated through a diverse portfolio of 1,250 retail stores across four brands, along with associated omnichannel consumer websites. National Vision operates through one reportable segment, Owned & Host, which includes two owned brands — America’s Best Contacts and Eyeglasses (America’s Best) and Eyeglass World.
Factors Favoring EYE’s Share Price Growth
National Vision’s share price is trending upward, prompted by its ongoing strategic transformation. The strategy focuses on four growth areas. In 2025, National Vision targeted underserved segments like managed care users and progressive lens wearers, boosting traffic. It also expanded premium and branded products, increasing sales and attracting higher-income customers, with strong performance from smart glasses and advanced lenses.
EYE is using data-driven segmentation to improve customer experience, personalize marketing and enhance sales practices, while leveraging its optometry network and technology to support steady expansion into new markets and formats.
In 2026, the company plans to open approximately 30 to 35 new stores, primarily comprising America’s Best locations, before returning to its more typical store opening cadence as strategic initiatives begin to take hold. New store openings are expected to remain a key driver of growth in net revenues and operating profit.
Investors are currently focused on the company’s strong market share gain in the Owned & Host segment. The segment continues to gain from positive comparable store sales growth and new store openings. Of the two Owned brands, America’s Best remains the primary revenue driver.
In the fourth quarter of 2025, adjusted comparable store sales growth was 4.8%. Remote exam technology remains central to National Vision’s ability to deliver care at scale. The company is making progress with its remote hybrid model, where in-store doctors also perform exams in other stores remotely. The program continues to expand, with more doctors being trained and participating.
National Vision’s 2026 outlook looks encouraging. Net revenues are projected to be in the range of $2.033-$2.091 billion. Adjusted EPS is estimated to be between 85 cents and $1.09.
Image Source: Zacks Investment Research
Factors That May Offset EYE’s Gains
EYE’s business remains vulnerable to growing geopolitical complexities, supply-chain disruptions, shortages of healthcare staff and volatility in capital markets. Additionally, the ongoing changes in U.S. trade policy and retaliatory tariffs look discouraging. All these factors continue to weigh on its profitability. In the fourth quarter of 2025, SG&A expenditures rose 12.1% year over year.
From a solvency viewpoint, National Vision has a significant amount of indebtedness. It exited the fourth quarter of 2025 with cash and cash equivalents of $39 million and short-term debt of $17 million. Long-term debt was $229 million, much higher than cash levels. This leverage could have several consequences, including greater exposure to adverse economic, industry or competitive developments.
A Look at EYE’s Estimates
The Zacks Consensus Estimate for 2026 EPS has remained unchanged at 93 cents in the past 30 days.
The company has an estimated long-term EPS growth rate of 20.1% compared with the industry’s 10.4%.
Stocks to Consider
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Alcon (ALC - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Globus Medical has an earnings yield of 4.9%, well ahead of the industry’s -0.7% yield. Its earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 18.8%. The company’s shares have rallied 22.3% against the industry’s 3.8% decline over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
ALC, carrying a Zacks Rank #2 (Buy) at present, has an earnings yield of 4.4% against the industry’s -1.1% yield. Shares of the company have lost 13.9% against the industry’s 2.3% growth. ALC’s earnings topped estimates in two of the trailing four quarters and missed in the other two, the average surprise being 1.1%.
Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 6.1% compared with the industry’s 2.6% yield. Shares of the company have climbed 130.6% against the industry’s 17.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 20.2%.